8+ hour, 58+ min ago   (124+ words) PharmaDispatch FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the…...

6+ day, 22+ hour ago   (138+ words) PharmaDispatch A review recommendation that should be reconsidered because of time A plan built around expanding the traditional evaluator pipeline, without first testing what AI can absorb, risks locking in permanent headcount and cost against a workload that may shrink…...

1+ week, 4+ hour ago   (139+ words) PharmaDispatch Bupa to discontinue international referrals for 'Doctors on Demand' telehealth Vitura Health has updated investors, confirming that Bupa will discontinue its international patient referrals from the Doctors on Demand telehealth business. … Five years, 1,826 days, and we are still going…...

1+ week, 11+ hour ago   (121+ words) Australian biotech Immuron takes gut health treatment to the US market PharmaDispatch Australian biotech Immuron takes gut health treatment to the US market Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an…...

1+ week, 16+ hour ago   (114+ words) PharmaDispatch Five years, 1,826 days, and we are still going on the HTA Review Today marks the fifth anniversary of former health minister Greg Hunt's announcement that Australia would conduct a review of health technology assessment. … The 'Dispatched' Week in Review…...

2+ week, 10+ hour ago   (140+ words) PharmaDispatch Alterity secures option underwriting as it prepares for pivotal MSA trial Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of…...

2+ week, 11+ hour ago   (134+ words) PharmaDispatch Avecho resumes pivotal insomnia trial recruitment after positive interim review Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study…...

2+ week, 5+ day ago   (143+ words) Entropy takes TRP-8803 to the US in head-to-head depression trial PharmaDispatch Entropy takes TRP-8803 to the US in head-to-head depression trial Entropy Neurodynamics has signed an agreement with the University of California, San Francisco, to develop a US Phase 2 trial…...

2+ week, 5+ day ago   (126+ words) PharmaDispatch Argent BioPharma takes CannEpil into US veterinary regulatory process Chairman Roby Zomer said the development marked the program’s transition from a commercial agreement into formal engagement with the FDA’s veterinary medicines division. … Australian study finds maternal RSV vaccination offers…...

3+ week, 10+ hour ago   (114+ words) PharmaDispatch Acrux brings experienced clinical leader aboard to advance female testosterone program Acrux has appointed physician and biopharmaceutical executive Dr Jolanta Airey as its chief medical officer, strengthening its leadership team as it prepares to advance its female testosterone treatment…...